These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 22535608

  • 1. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
    Mataraci EA, Ozgüven BY, Kabukçuoglu F.
    Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
    Abd-El Raouf SM, Ibrahim TR.
    Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
    [Abstract] [Full Text] [Related]

  • 4. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
    Rossi ED, Raffaelli M, Mule' A, Miraglia A, Lombardi CP, Vecchio FM, Fadda G.
    Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.
    Murtezaoglu AR, Gucer H.
    Pol J Pathol; 2017 Jun; 68(1):1-10. PubMed ID: 28547974
    [Abstract] [Full Text] [Related]

  • 6. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19.
    Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO.
    Endocr Pathol; 2010 Jun; 21(2):80-9. PubMed ID: 20198455
    [Abstract] [Full Text] [Related]

  • 7. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules.
    Cui W, Sang W, Zheng S, Ma Y, Liu X, Zhang W.
    Clin Lab; 2012 Jun; 58(7-8):673-80. PubMed ID: 22997967
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
    Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X, Zhu X.
    J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
    [Abstract] [Full Text] [Related]

  • 9. [Low galectin-3 capacity to discriminate thyroid lesions].
    De-León-Mazariegos R, Canedo-Patzi M, Pérez-Enríquez B, Candanedo-Gonzalez F, Saqui-Salces M, Gamboa-Domínguez A, Rull-Rodrigo JA.
    Rev Invest Clin; 2004 Sep; 56(5):623-8. PubMed ID: 15776867
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.
    Paunovic I, Isic T, Havelka M, Tatic S, Cvejic D, Savin S.
    APMIS; 2012 May; 120(5):368-79. PubMed ID: 22515291
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma.
    Scognamiglio T, Hyjek E, Kao J, Chen YT.
    Am J Clin Pathol; 2006 Nov; 126(5):700-8. PubMed ID: 17050067
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.
    Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park DJ, Jang HC, Park SH, Cho BY, Park SY.
    J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499
    [Abstract] [Full Text] [Related]

  • 15. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma.
    Nga ME, Lim GS, Soh CH, Kumarasinghe MP.
    Diagn Cytopathol; 2008 Aug; 36(8):550-6. PubMed ID: 18618720
    [Abstract] [Full Text] [Related]

  • 16. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
    Ceyran AB, Şenol S, Şimşek BÇ, Sağıroğlu J, Aydın A.
    Int J Clin Exp Pathol; 2015 Aug; 8(4):3670-80. PubMed ID: 26097548
    [Abstract] [Full Text] [Related]

  • 17. Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using HBME-1 and CD56.
    Nechifor-Boila A, Borda A, Sassolas G, Hafdi-Nejjari Z, Borson-Chazot F, Lifante JC, Sturm N, Lavérriere MH, Berger N, Decaussin-Petrucci M.
    Pathol Res Pract; 2013 Sep; 209(9):585-92. PubMed ID: 23910176
    [Abstract] [Full Text] [Related]

  • 18. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
    Than TH, Swethadri GK, Wong J, Ahmad T, Jamil D, Maganlal RK, Hamdi MM, Abdullah MS.
    Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic value of HBME-1, CK19, Galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma.
    Cho H, Kim JY, Oh YL.
    Pathol Int; 2018 Nov; 68(11):605-613. PubMed ID: 30350394
    [Abstract] [Full Text] [Related]

  • 20. Intensity and distribution of immunohistochemical expression of galectin-3 in thyroid neoplasms.
    Matesa-Anić D, Moslavac S, Matesa N, Cupić H, Kusić Z.
    Acta Clin Croat; 2012 Jun; 51(2):237-41. PubMed ID: 23115948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.